Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma have?
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma has 3,424 citations in the OpenAlex counts ScholarIQ stores.
When was Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma published?
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma has 2017 year in the ScholarIQ index.
What is the open-access status of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma?
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma has bronze oa status in the ScholarIQ index.
What is the DOI of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma?
The DOI for Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma is on the source record.
What is the PMID of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma?
The PMID for Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma is on the source record.
What is the OpenAlex record for Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma?
The OpenAlex for Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma is on the source record.